Literature DB >> 728898

Response of murine leukemia to combined BCNU-maleic anhydride-vinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay.

J H Dean, M L Padarathsingh, L Keys.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 728898

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

1.  Phase I study of MVE-2 evaluating toxicity and biologic response modification capability.

Authors:  J D Hainsworth; J T Forbes; W W Grosh; F A Greco
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Phase II trial of MVE-II in metastatic malignant melanoma.

Authors:  J Rinehart; J LaForge; D Gochnour; J Neidhart
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Immune functions in methyl and ethyl carbamate treated mice.

Authors:  M I Luster; J H Dean; G A Boorman; M P Dieter; H T Hayes
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

4.  Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2).

Authors:  M G Rosenblum; A M Rios; E M Hersh
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Peritoneal macrophage alterations caused by naturally occurring mouse hepatitis virus.

Authors:  G A Boorman; M I Luster; J H Dean; M L Campbell; L A Lauer; F A Talley; R E Wilson; M J Collins
Journal:  Am J Pathol       Date:  1982-01       Impact factor: 4.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.